Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus LOSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus LOSARTAN.
AVALIDE vs Losartan
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Losartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to the AT1 receptor, thereby antagonizing vasoconstriction, aldosterone secretion, and renal sodium reabsorption, leading to reduced blood pressure.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Losartan 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
None Documented
None Documented
Clinical Note
moderateLosartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid."
Clinical Note
moderateLosartan + Furosemide
"The risk or severity of adverse effects can be increased when Losartan is combined with Furosemide."
Clinical Note
moderateLosartan + Bumetanide
"The risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide."
Clinical Note
moderateLosartan + Benzydamine
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Terminal half-life: 6-9 hours (losartan), 6-9 hours (active metabolite E-3174); clinical context: once-daily dosing is sufficient due to prolonged receptor binding
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Renal: 50% (parent drug and active metabolite), Biliary/Fecal: 50%
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB
"The risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine."